Survival and prognosis of patients with astrocytoma with atypical or anaplastic features

Author(s): Nelson D, Nelson J, Davis D, Chang C, Griffins T, et al.

Abstract

This study confirms the importance of histologic tumor necrosis as a major prognostic variable in malignant glioma. Necrosis is present in glioblastoma multiforme (GBM), and absent in astrocytoma with atypical or anaplastic features (AAF). This paper evaluates 94 patients with AAF and 462 patients with GBM treated with radiation therapy with or without BCNU on 3 consecutive randomized protocols of the Radiation Therapy Oncology Group (RTOG) between 1974 and 1983. Multivariate analyses of the 556 patients confirmed histology as a significant independent variable that is prognostically relatively more important than Karnofsky performance status (KPS) and extent of surgery, and somewhat less important than age. The median survival for AAF was 36.2 months and for GBM was 8.6 months. In addition, separate multivariate analyses of AAf cases determined that the extent of surgery is a significant independent variable that is relatively more important than KPS, but less important than age. The median survival of AAF patients who underwent surgical excision was 46.8 months compared with 15.2 months for those biopsied (p < .001).

Similar Articles

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Author(s): Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al.

Radium-223 in the treatment of osteoblastic metastases: a critical clinical review

Author(s): Humm JL, Sartor O, Parker C, Bruland OS, Macklis R

Alpha emitter radium-223 and survival in metastatic prostate cancer

Author(s): Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al.

Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis

Author(s): Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P

Effect of nanoparticle surface charge at the plasma membrane and beyond

Author(s): Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, et al.

Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles

Author(s): Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, et al.

Switching the Targeting Pathways of a Therapeutic Antibody by Nanodesign

Author(s): Bhattacharyya S, Singh RD, Pagano R, Robertson JD, Bhattacharya R, et al.

Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors

Author(s): Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, et al.

LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy

Author(s): McLaughlin MF, Robertson D, Pevsner PH, Wall JS, Mirzadeh S, et al.

LaPO4 Nanoparticles Doped with Actinium-225 that Partially Sequester Daughter Radionuclides

Author(s): Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, et al.

Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy

Author(s): McLaughlin MF, Woodward J, Boll RA, Wall JS, Rondinone AJ, et al.

Bioelectric effects of intense ultrashort pulses

Author(s): Joshi RP, Schoenbach KH

Nanosecond pulsed electric field thresholds for nanopore formation in neural cells

Author(s): Roth CC, Tolstykh GP, Payne JA, Kuipers MA, Thompson GL